MACH32 INC.
$80,000.00 CAD
≈ 12 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- August 1, 2025 – June 30, 2026
- Reference
- nrc-cnrc:172-2025-2026-Q2-1033871
Published purpose
This project aims to develop a smaller, intramuscular autoinjector capable of delivering a concentrated formulation of tranexamic acid (TXA), a widely used antifibrinolytic for treating hemorrhage. The Firm’s current prototype can deliver up to 5 mL; however, user feedback from military and emergency responders indicates a strong preference for a more compact device. By formulating TXA at higher concentrations, the Firm has reduced the required injection volume to 2–3 mL. This enables the design of a smaller, more field-appropriate autoinjector without compromising therapeutic efficacy.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions